• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

139
19
13
13
11

COUNTRY

5
4
4
4
3

PRICE

6
90
122
496

PUBLISHED

1
13
123
496

PRODUCT TYPE

488
5
2
1

Immune Disorders

(496 Products)

More than 150 primary immunodeficiency diseases (PIDs) have been identified, a number that does not include acquired immunodeficiencies. Examples of immune disorders include Type 1 diabetes, rheumatoid arthritis, allergies, Crohn’s Disease, and HIV, which infects over 0.5% of the world’s population.

In the reports and subscriptions listed under Research and Markets’ category you will find pipeline assessments of drugs and therapeutics, market forecasts, investment and growth opportunities, and much more. Also explored in-depth is the key role of immune response and pharmaceuticals in transplant medicine, with reviews of clinical trials, market trends and major companies in the areas of lung transplants, liver transplants, transplant inflammation/rejection, etc.

Key players profiled include Abbott Laboratories, Pfizer, Johnson & Johnson, Biogen Idec, Amgen, Bayer AG, Sanofi, and more. Show Less
Read more

PRODUCT TITLE

Simponi (Rheumatoid Arthritis) Forecast and Market Analysis

Simponi (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Simponi (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM

Tabalumab (Rheumatoid Arthritis) Forecast and Market Analysis

Tabalumab (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Tabalumab (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM

Secukinumab (Rheumatoid Arthritis) Forecast and Market Analysis

Secukinumab (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Secukinumab (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM

PharmaPoint: Rheumatoid Arthritis - China Drug Forecast and Market Analysis Event-Driven Update

PharmaPoint: Rheumatoid Arthritis - China Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - China Drug...

November 2012
FROM

PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis Event-Driven Update

PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - Australia...

November 2012
FROM

Orencia (Rheumatoid Arthritis) Forecast and Market Analysis

Orencia (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Orencia (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM

Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis

Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM

Actemra (Rheumatoid Arthritis) Forecast and Market Analysis

Actemra (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Actemra (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM

PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update

PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - India Drug...

November 2012
FROM

Sirukumab (Rheumatoid Arthritis) Forecast and Market Analysis

Sirukumab (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Sirukumab (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM

Enbrel (Rheumatoid Arthritis) Forecast and Market Analysis

Enbrel (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Enbrel (Rheumatoid Arthritis) Forecast and Market Analysis. The...

November 2012
FROM

PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast and Market Analysis Event-Driven Update

PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis...

November 2012
FROM

Remicade (Rheumatoid Arthritis) Forecast and Market Analysis

The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab...

November 2012
FROM

Masitinib (Rheumatoid Arthritis) Forecast and Market Analysis

Masitinib (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Masitinib (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM

PharmaPoint: Rheumatoid Arthritis - Italy Drug Forecast and Market Analysis Event-Driven Update

PharmaPoint: Rheumatoid Arthritis - Italy Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - Italy Drug...

November 2012
FROM

Fostamatinib (Rheumatoid Arthritis) Forecast and Market Analysis

Fostamatinib (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Fostamatinib (Rheumatoid Arthritis) Forecast and Market...

November 2012
FROM

PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis Event-Driven Update

PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis -...

November 2012
FROM
Olive Allergy - Pipeline Review, H2 2012 Olive Allergy - Pipeline Review, H2 2012 - Product Thumbnail Image

Olive Allergy - Pipeline Review, H2 2012

Olive Allergy – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Olive Allergy - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides...

November 2012
FROM
Axial Spondyloarthritis - Pipeline Review, H2 2012 Axial Spondyloarthritis - Pipeline Review, H2 2012 - Product Thumbnail Image

Axial Spondyloarthritis - Pipeline Review, H2 2012

Axial Spondyloarthritis – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Axial Spondyloarthritis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline....

November 2012
FROM
Grass Pollen Allergy - Pipeline Review, H2 2012 Grass Pollen Allergy - Pipeline Review, H2 2012 - Product Thumbnail Image

Grass Pollen Allergy - Pipeline Review, H2 2012

Grass Pollen Allergy – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Grass Pollen Allergy - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This...

November 2012
FROM
Loading Indicator

Our Clients

Merck & Co., Inc. Celgene Corporation GlaxoSmithKline PLC Genentech, Inc. Johnson & Johnson Services, Inc. ViiV Healthcare